Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Autoimmune Basis for Postural Tachycardia Syndrome

NCT: NCT05043051 · ACTIVE_NOT_RECRUITING

NCT IDNCT05043051
StatusACTIVE_NOT_RECRUITING
Start Date2022-01-14
Completion2026-07-31

Brief Summary

The purpose of this study is to test the hypothesis that an antibody-mediated autoimmune reaction will cause symptoms of autonomic dysfunction in some patients with postural tachycardia syndrome (POTS). The investigators further hypothesize that electrical stimulation of the vagus nerve will improve POTS symptoms, autoimmunity and inflammation.

Frequently Asked Questions

What is Autoimmune Basis for Postural Tachycardia Syndrome?

Autoimmune Basis for Postural Tachycardia Syndrome is a clinical trial registered under NCT05043051. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05043051?

The current status of NCT05043051 (Autoimmune Basis for Postural Tachycardia Syndrome) is: ACTIVE_NOT_RECRUITING.

When did Autoimmune Basis for Postural Tachycardia Syndrome start?

Autoimmune Basis for Postural Tachycardia Syndrome started on 2022-01-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.